Mounjaro for Weight Management and Type 2 Diabetes
Mounjaro (tirzepatide) is indicated for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. It is also approved for the treatment of adults with type 2 diabetes mellitus to improve glycemic control, alongside diet and exercise.
Mounjaro is a once-weekly injection that mimics the action of both GLP-1 and GIP hormones, helping to regulate appetite, glucose levels, and food intake, resulting in significant weight loss.
Type of Medicine | A dual GLP-1 and GIP receptor agonist |
---|---|
Used for | Chronic weight management and management of type 2 diabetes in adults |
Also called | Tirzepatide |
Available as | Injections |
Tirzepatide helps achieve an average weight loss of approximately 20% by reducing appetite and increasing feelings of fullness, which leads to decreased caloric intake. It is used as part of a comprehensive treatment program that includes lifestyle changes like diet and exercise.
What is Tirzepatide available as?
- Injections: Available in a single pen containing doses for 4 weeks.
When should I give Tirzepatide?
Mounjaro is administered once a week on the same day each week. You can inject it at any time of day, with or without food, but maintaining a consistent schedule is recommended.
How much should I give?
Your healthcare provider will determine the appropriate dosage based on your weight management or diabetes control goals. Treatment typically starts with a specific dose, which may be adjusted based on your response and tolerability.